Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Glioblastoma (GBM) is a highly aggressive brain tumor characterized by therapy-resistant glioma stem cells (GSCs).
• The mitogen-activated protein kinase (MAPK) pathway, including MAPK-interacting kinases (MNK1/2), plays a crucial role in GBM progression by regulating mRNA translation.
• Existing MNK inhibitors often lack specificity, necessitating the development of more targeted therapeutic strategies.

Purpose of the Study:

• To develop novel, specific MNK inhibitors for GBM treatment.
• To identify combination therapies that enhance the efficacy of MNK inhibition in GBM and GSCs.
• To investigate the therapeutic potential of dual MNK and DNA methyltransferase (DNMT) inhibition.

Main Methods:

• Medicinal chemistry was used to optimize novel MNK inhibitor compounds.
• Antineoplastic activity was assessed in GBM cell lines and patient-derived GSCs using 3-D neurosphere models.
• Molecular docking, kinome profiling, immunoblotting, flow cytometry, and various functional assays were employed.
• A compound screen identified DNMT inhibitors as potential enhancers of MNK-targeted therapy.

Main Results:

• A next-generation MNK inhibitor, NUCC-201893, demonstrated high specificity and potency, suppressing GBM cell viability, migration, and invasion.
• Compound screening revealed that DNA methyltransferase (DNMT) inhibition synergizes with MNK blockade.
• Combined MNK and DNMT inhibition significantly enhanced cytotoxic effects, suppressed neurosphere growth, and induced apoptosis in GSCs.

Conclusions:

• Dual inhibition of MNK and DNMT represents a promising combinatorial strategy for GBM therapy.
• This approach effectively targets both GBM cells and GSCs, leading to significant antineoplastic effects.
• Further investigation into MNK and DNMT dual inhibition could lead to improved clinical outcomes for GBM patients.